VITA-GBM: EPIC-0502-driven HIF1α degradation overcomes bevacizumab resistance and synergizes with TMZ in glioblastoma
Based on EPIC-0502-driven HIF1α degradation that overcomes BEV resistance and synergizes with TMZ, we propose the novel VITA-GBM regimen comprising: Vascular targeting (BEV), Inhibition of hypoxia signaling (EPIC-0502), TMZ chemotherapy, and Alignment of synergistic mechanisms. This strategy enhances the efficacy of first-line therapies and provides a promising approach to improve overall survival in GBM patients.
Authors
- Biao Hong
- Yaqing Ding
- Dongyuan Su
- Yuhao Liu (ORCID: https://orcid.org/0000-0002-1666-208X)
- Xing Cui (ORCID: https://orcid.org/0000-0002-8771-5898)
- Yilin Zhao (ORCID: https://orcid.org/0009-0003-3011-2193)
- Xinyu Zhao (ORCID: https://orcid.org/0000-0002-5128-4424)
- Hanyi Xu
- Longtao Cui
- Cai Cheng (ORCID: https://orcid.org/0009-0004-8797-1244)
- Yanping Huang
- Chunsheng Kang
- Qixue Wang
- Qi Zhan
- Siwen Liang
Institutions
- Tianjin Medical University General Hospital (CN)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2025-12-29
- DOI
- https://doi.org/10.1093/neuonc/noaf293
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00